Q-omics provides the consensus-scored CD300A profile across patient tissues and cancer cell-line models. CD300A expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, CD300A is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, CD300A protein abundance shows 23,208 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UVM, KIRC, and LSCC as cancer lineages where CD300A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CD300A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CD300A survival associations across molecular data types. CD300A RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CD300A RNA expression–survival associations across cancer types. High CD300A expression shows unfavorable associations in UVM, ACC, LGG and LAML, but favorable associations in SKCM and HNSC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for CD300A RNA expression.
This table summarizes CD300A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for CD300A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CD300A shows lower tumor expression in LUSC and higher tumor expression in KIRC, KIRP, HNSC, THCA and STAD. The KIRC box plot shows higher CD300A RNA expression in tumor versus normal tissue (log2 FC = +2.973, t-test p < 0.001).
This table shows molecular features associated with CD300A in patient tissues and cancer cell lines. In patient samples, CD300A shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, CD300A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BLOOD_Leukemia.
